Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DJO sued over ReAble deal

This article was originally published in The Gray Sheet

Executive Summary

Shareholders of orthopedic device maker DJO file class action lawsuit in San Diego state court Aug. 31 seeking an injunction on the company's pending $1.6 billion sale to ReAble Therapeutics, claiming that the price is inadequate. The complaint alleges that DJO and its board approved the sale in July without shopping the firm to other potential buyers or fully informing themselves of its value (1"The Gray Sheet" July 23, 2007, p. 6). DJO says it will "vigorously oppose" the allegations, although it expects additional suits with similar claims

You may also be interested in...

ReAble Makes $1.6 Billion Move To Acquire Ortho Rehab Firm DJO

ReAble Therapeutics agreed July 16 to buy DJO for about $1.6 billion in a deal that will give the privately held firm a substantial stake in the bracing and soft goods orthopedic market and complement its current strength in electrotherapy pain management

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts